Dr. Göran Ando is proposed for election to Initiator Pharma’s Board of Directors and appointed as senior advisor in business development

Regulatory

Initiator Pharma A/S, a clinical-stage pharma company developing innovative drugs targeting unmet medical needs within the central and peripheral nervous system, today announced that Dr. Göran Ando, former Chairman of Novo Nordisk A/S, is proposed for election to the company’s Board of Directors at the 2025 AGM. Dr. Ando is also appointed as an advisor supporting the Board and management team, effective immediately.

”I am very pleased that Dr. Ando has accepted the role as advisor and the nomination to Initiator Pharma’s board. Dr. Ando is one of the most distinguished world leaders in the pharmaceutical industry, not least through his long tenure as Chairman of Novo Nordisk. His experience and network will be of immense value to us”, says Magnus Persson, Chairman of the Board at Initiator Pharma.

"Initiator Pharma has an exciting and promising project portfolio targeting areas with high medical need, and a leadership team that has impressed me in our discussions. I look forward to supporting the team in the continued value creation of Initiator Pharma”, says Dr. Göran Ando.

Dr. Göran Ando’s prominent career in the global pharmaceutical industry spans over more than four decades. Dr. Ando’s previous board assignments include Vice Chairman and Chairman at Novo Nordisk A/S between 2006 and 2018. He is also Chairman of the Board for Nouscom A/G in Switzerland, Nanexa AB in Sweden, and Eyepoint Pharmaceuticals in the US. He began his career at Pfizer, holding several senior clinical positions in both the U.S. and Europe. Dr. Ando also served as President of the Astra Research Centre and held senior appointments at GlaxoSmithKline, including R&D Director for Glaxo Group Research. In 1995, he joined Pharmacia as Executive Vice President and Deputy CEO, and during his tenure at Pharmacia/Pharmacia & Upjohn 17 new drugs were approved by the FDA before Pharmacia was acquired by Pfizer for $60 billion. He was the CEO of Cell Tech Group from 2003 to 2005 and Senior Advisor at EW Healthcare Partners from 2007 to 2021.

Dr. Ando holds a Bachelor of Arts degree from Uppsala University in Sweden and a Doctor of Medicine degree from Linköping University in Sweden.

For additional information about Initiator Pharma, please contact:

Claus Elsborg Olesen, CEO
Telephone: +45 6126 0035
E-mail: [email protected]

About Initiator Pharma

Initiator Pharma A/S is a Danish clinical stage emerging pharma company developing innovative drugs that target key unmet medical needs within the central and peripheral nervous system. Initiator Pharma’s pipeline consists of two clinical stage assets – pudafensine and IP2018 – and two preclinical assets. With pudafensine the company has reported positive, statistically significant and clinically relevant efficacy data in a Phase IIb clinical trial with patients suffering from ED. With IP2018 the company has reported positive, statistically significant, and dose-dependent clinical observations related to efficacy in psychogenic erectile dysfunction (ED) in a Phase IIa clinical trial of IP2018 in patients with mild to moderate ED.
 
Initiator Pharma is listed on Nasdaq First North Growth Market (ticker: INIT). Redeye AB is the company’s Certified Adviser. For more information, please visit www.initiatorpharma.com.

This information is information that Initiator Pharma is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-03-25 08:30 CET.

Attachments

Dr. Göran Ando is proposed for election to Initiator Pharma’s Board of Directors and appointed as senior advisor in business development

Documents